This is a plain language summary of two articles describing the results from a study called BLC2001. The study examined the effect of a medication called erdafitinib on participants with a type of cancer known as urothelial carcinoma that had either spread beyond the bladder or urinary tract into surrounding organs and/or nearby muscles (locally advanced) and was not removable by surgery (unresectable) or had spread to other parts of the body (metastatic)This Plain Language Summary of Publication article from Future Oncology describes the results from a study that examined the effectiveness of a medication called erdafitinib on participants with a type of cancer known as urothelial carcinoma.

Visit the Future Medicine site using the link to read the article.

The summary is based on two original articles.

  • ‘Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma’ which was published in The New England Journal of Medicine. Visit the New England Journal of Medicine site using the link to read the article.
  • ‘Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study’ which was published in The Lancet Oncology. Visit The Lancet site using the link to read the article.